<DOC>
	<DOCNO>NCT00002330</DOCNO>
	<brief_summary>To compare time progression Cytomegalovirus ( CMV ) retinitis among three dos oral ganciclovir , well intravenous therapy , give maintenance 26 week . To compare safety tolerance among oral dos ganciclovir study dos , well intravenous therapy , administer maintenance 26 week .</brief_summary>
	<brief_title>A Study Two Forms Ganciclovir Treatment Cytomegalovirus ( CMV ) Eyes Patients With AIDS</brief_title>
	<detailed_description>Patients receive anti-CMV therapy intravenous ganciclovir least 4 week result stable retinitis randomize receive one three dose oral ganciclovir intravenous ganciclovir 26 week maintenance .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Topical ophthalmic nucleoside analogue . Patients must : HIV positive . No two episode CMV retinitis progression ( relapse result reinduction intravenous antiCMV therapy ) since original retinitis diagnosis . Currently stable retinitis . Prior Medication : Allowed : Foscarnet prior 4 week intravenous induction therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Persistent clinically significant diarrhea , nausea , abdominal pain . Severe odynophagia . Other gastrointestinal ( GI ) symptom uncontrolled GI disease . Active CMV disease GI tract ( e.g. , CMV colitis , CMV esophagitis ) . Ocular medium opacity ( corneal , lenticular , vitreal ) prevent ophthalmologic retinal assessment . Dementia , decrease mentation , encephalopathic sign symptom would preclude informed consent study compliance . Concurrent Medication : Excluded : Acyclovir sodium ( Zovirax ) route topical . Valacyclovir . Brovavir . Vidarabine . Amantadine hydrochloride . Cytarabine . Idoxuridine . Ribavirin . Interferon . Foscarnet ( nonnucleoside pyrophosphate analogue ) . CMV hyperimmune globulin . Soluble CD4 . Trichosanthin ( Compound Q ) . Imipenemcilastatin . Isoprinosine . Levamisole . Other investigational drug . Patients follow prior condition exclude : History hypersensitivity acyclovir ganciclovir . Prior Medication : Excluded : More three induction regimens intravenous antiCMV therapy . Any prior oral ganciclovir .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>